Metabolic brain mapping in Alzheimer's disease using proton magnetic resonance spectroscopy

François Lazeyras, H. Cecil Charles, Larry A. Tupler, Renata Erickson, Orest Boyko, K. Ranga Rama Krishnan

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Alzheimer's disease (AD) is a progressive disorder associated with disruption of neuronal function and neuronal loss. N-acetylaspartate (NAA) is a marker of neuronal content and can be assessed using proton (1H) magnetic resonance spectroscopy (MRS). We utilized 1H-MRS (two-dimensional chemical- shift imaging) to assess amplitudes and areas of NAA, as well as choline moieties (Cho), creatine (Cr) and myo-inositol (mI), in 15 AD patients compared with 14 control subjects. Voxels were classified as predominantly cortical gray matter (CGM), subcortical gray matter (SGM), or white matter (WM). Compared with control subjects, AD patients exhibited decreased NAA/Cho and NAA/Cr amplitudes, whereas an increase was observed in Cho/Cr and in amplitude ratios involving mI. Area ratios were significant in the same direction for NAA/Cho, NAA/Cr, mI/Cr and mI/NAA. No significant effects of tissue type were observed; however, significant group x tissue type interactions were noted for Cho/Cr and mI/Cr amplitudes. Our study confirms that 1H-MRS can identify distinct physicochemical alterations in AD patients, reflecting membrane changes and diminished neuronal function. These alterations can be used as longitudinal markers for the disease.

Original languageEnglish (US)
Pages (from-to)95-106
Number of pages12
JournalPsychiatry Research - Neuroimaging
Volume82
Issue number2
DOIs
StatePublished - May 20 1998
Externally publishedYes

Fingerprint

Brain Mapping
Creatine
Alzheimer Disease
Inositol
Magnetic Resonance Spectroscopy
Choline
N-acetylaspartate
Proton Magnetic Resonance Spectroscopy
Magnetic Resonance Imaging
Membranes

Keywords

  • H-MRS
  • Alzheimer's disease
  • myo-inositol
  • Physicochemical

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Radiology Nuclear Medicine and imaging
  • Biological Psychiatry
  • Psychology(all)

Cite this

Lazeyras, F., Charles, H. C., Tupler, L. A., Erickson, R., Boyko, O., & Krishnan, K. R. R. (1998). Metabolic brain mapping in Alzheimer's disease using proton magnetic resonance spectroscopy. Psychiatry Research - Neuroimaging, 82(2), 95-106. https://doi.org/10.1016/S0925-4927(98)00010-9

Metabolic brain mapping in Alzheimer's disease using proton magnetic resonance spectroscopy. / Lazeyras, François; Charles, H. Cecil; Tupler, Larry A.; Erickson, Renata; Boyko, Orest; Krishnan, K. Ranga Rama.

In: Psychiatry Research - Neuroimaging, Vol. 82, No. 2, 20.05.1998, p. 95-106.

Research output: Contribution to journalArticle

Lazeyras, F, Charles, HC, Tupler, LA, Erickson, R, Boyko, O & Krishnan, KRR 1998, 'Metabolic brain mapping in Alzheimer's disease using proton magnetic resonance spectroscopy', Psychiatry Research - Neuroimaging, vol. 82, no. 2, pp. 95-106. https://doi.org/10.1016/S0925-4927(98)00010-9
Lazeyras, François ; Charles, H. Cecil ; Tupler, Larry A. ; Erickson, Renata ; Boyko, Orest ; Krishnan, K. Ranga Rama. / Metabolic brain mapping in Alzheimer's disease using proton magnetic resonance spectroscopy. In: Psychiatry Research - Neuroimaging. 1998 ; Vol. 82, No. 2. pp. 95-106.
@article{2e3be9dc9155420ba3d9b71195f25177,
title = "Metabolic brain mapping in Alzheimer's disease using proton magnetic resonance spectroscopy",
abstract = "Alzheimer's disease (AD) is a progressive disorder associated with disruption of neuronal function and neuronal loss. N-acetylaspartate (NAA) is a marker of neuronal content and can be assessed using proton (1H) magnetic resonance spectroscopy (MRS). We utilized 1H-MRS (two-dimensional chemical- shift imaging) to assess amplitudes and areas of NAA, as well as choline moieties (Cho), creatine (Cr) and myo-inositol (mI), in 15 AD patients compared with 14 control subjects. Voxels were classified as predominantly cortical gray matter (CGM), subcortical gray matter (SGM), or white matter (WM). Compared with control subjects, AD patients exhibited decreased NAA/Cho and NAA/Cr amplitudes, whereas an increase was observed in Cho/Cr and in amplitude ratios involving mI. Area ratios were significant in the same direction for NAA/Cho, NAA/Cr, mI/Cr and mI/NAA. No significant effects of tissue type were observed; however, significant group x tissue type interactions were noted for Cho/Cr and mI/Cr amplitudes. Our study confirms that 1H-MRS can identify distinct physicochemical alterations in AD patients, reflecting membrane changes and diminished neuronal function. These alterations can be used as longitudinal markers for the disease.",
keywords = "H-MRS, Alzheimer's disease, myo-inositol, Physicochemical",
author = "Fran{\cc}ois Lazeyras and Charles, {H. Cecil} and Tupler, {Larry A.} and Renata Erickson and Orest Boyko and Krishnan, {K. Ranga Rama}",
year = "1998",
month = "5",
day = "20",
doi = "10.1016/S0925-4927(98)00010-9",
language = "English (US)",
volume = "82",
pages = "95--106",
journal = "Psychiatry Research - Neuroimaging",
issn = "0925-4927",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Metabolic brain mapping in Alzheimer's disease using proton magnetic resonance spectroscopy

AU - Lazeyras, François

AU - Charles, H. Cecil

AU - Tupler, Larry A.

AU - Erickson, Renata

AU - Boyko, Orest

AU - Krishnan, K. Ranga Rama

PY - 1998/5/20

Y1 - 1998/5/20

N2 - Alzheimer's disease (AD) is a progressive disorder associated with disruption of neuronal function and neuronal loss. N-acetylaspartate (NAA) is a marker of neuronal content and can be assessed using proton (1H) magnetic resonance spectroscopy (MRS). We utilized 1H-MRS (two-dimensional chemical- shift imaging) to assess amplitudes and areas of NAA, as well as choline moieties (Cho), creatine (Cr) and myo-inositol (mI), in 15 AD patients compared with 14 control subjects. Voxels were classified as predominantly cortical gray matter (CGM), subcortical gray matter (SGM), or white matter (WM). Compared with control subjects, AD patients exhibited decreased NAA/Cho and NAA/Cr amplitudes, whereas an increase was observed in Cho/Cr and in amplitude ratios involving mI. Area ratios were significant in the same direction for NAA/Cho, NAA/Cr, mI/Cr and mI/NAA. No significant effects of tissue type were observed; however, significant group x tissue type interactions were noted for Cho/Cr and mI/Cr amplitudes. Our study confirms that 1H-MRS can identify distinct physicochemical alterations in AD patients, reflecting membrane changes and diminished neuronal function. These alterations can be used as longitudinal markers for the disease.

AB - Alzheimer's disease (AD) is a progressive disorder associated with disruption of neuronal function and neuronal loss. N-acetylaspartate (NAA) is a marker of neuronal content and can be assessed using proton (1H) magnetic resonance spectroscopy (MRS). We utilized 1H-MRS (two-dimensional chemical- shift imaging) to assess amplitudes and areas of NAA, as well as choline moieties (Cho), creatine (Cr) and myo-inositol (mI), in 15 AD patients compared with 14 control subjects. Voxels were classified as predominantly cortical gray matter (CGM), subcortical gray matter (SGM), or white matter (WM). Compared with control subjects, AD patients exhibited decreased NAA/Cho and NAA/Cr amplitudes, whereas an increase was observed in Cho/Cr and in amplitude ratios involving mI. Area ratios were significant in the same direction for NAA/Cho, NAA/Cr, mI/Cr and mI/NAA. No significant effects of tissue type were observed; however, significant group x tissue type interactions were noted for Cho/Cr and mI/Cr amplitudes. Our study confirms that 1H-MRS can identify distinct physicochemical alterations in AD patients, reflecting membrane changes and diminished neuronal function. These alterations can be used as longitudinal markers for the disease.

KW - H-MRS

KW - Alzheimer's disease

KW - myo-inositol

KW - Physicochemical

UR - http://www.scopus.com/inward/record.url?scp=0032550737&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032550737&partnerID=8YFLogxK

U2 - 10.1016/S0925-4927(98)00010-9

DO - 10.1016/S0925-4927(98)00010-9

M3 - Article

VL - 82

SP - 95

EP - 106

JO - Psychiatry Research - Neuroimaging

JF - Psychiatry Research - Neuroimaging

SN - 0925-4927

IS - 2

ER -